SelenBio, Inc.
OperatingSelenBio, Inc
Biotech · Founded 2017
SelenBio, Inc. is a biotechnology company developing antibacterial technology for a wide variety of use cases.
Financials
FY2017–FY2023 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Share counts as of Dec 31, 2021| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 5,687,814 | — | 100.0% | $4.00Oct 2019 |
Shares outstanding over timein today's share terms
Principal holders% as the filing states it, May 30, 2024
- Karl Doenges31.7%of company
- Kenny Gallagher30.9%of company
Sold to the crowd
- Reg CF · Oct 201937,043 shares at $4.00$148.2K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
2 peopleNames and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 5 of 7 annual reports (FY2019–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 12 filings on EDGAR- Form C-TRMay 30, 20240001787006-24-000003EDGAR
- Form C-ARMay 30, 20240001787006-24-000001EDGAR
- Form C-ARApr 28, 20230001669191-23-000389EDGAR
- Form C-ARApr 27, 20220001669191-22-000439EDGAR
- Form C-ARApr 27, 20210001669191-21-000438EDGAR
- Form C-ARJun 12, 20200001669191-20-000309EDGAR
- Form C-UApr 29, 20200001669191-20-000208EDGAR
- Form C/AMar 27, 20200001669191-20-000146EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.